Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of liraglutide capsule in China. Welcome to wholesale bulk high quality liraglutide capsule for sale here from our factory. Good service and reasonable price are available.
Liraglutide capsule is an oral formulation of a new-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is a polypeptide hypoglycemic and weight-loss drug engineered based on the structure of native human GLP-1, sharing up to 97% amino acid sequence homology with endogenous human GLP-1 while possessing outstanding bioactivity and metabolic stability. Compared with traditional injectable dosage forms, the capsule formulation breaks through the oral absorption barrier of peptide drugs and greatly improves patient medication adherence, making it one of the core therapeutic agents for clinical management of metabolic disorders.
Products Description
Additional information of chemical compound:
Liraglutide COA
Core Pharmacological Mechanisms
Mechanism of Molecular Structural Modification and Stability Regulation
The pharmacological activity of liraglutide capsule is grounded in precise artificial molecular modification, which retains the receptor-binding activity of native GLP-1 while fundamentally resolving the clinical limitation of ultra-short half-life of endogenous GLP-1. Native human GLP-1 is rapidly recognized, cleaved and degraded by DPP-4 enzymes in vivo, with a half-life of merely 1–2 minutes, rendering it unsuitable for long-acting clinical application. Liraglutide achieves enhanced stability via two critical structural alterations:
Substitution of lysine at position 34 of native GLP-1 with arginine. This site modification does not alter the binding affinity between the drug and GLP-1 receptors yet completely eliminates the specific recognition site for DPP-4, preventing rapid drug degradation at the source.
Covalent conjugation of a C16 palmitic fatty acid side chain to the lysine residue at position 26 via a γ-glutamic acid linker. This fatty acid side chain serves as the core structural moiety for long-acting performance. Upon entering systemic circulation, it undergoes reversible non-covalent binding with plasma albumin to form a drug-albumin complex.
This binding masks degradation sites on drug molecules, reduces glomerular filtration and clearance of the drug, and drastically slows metabolic elimination, prolonging the in vivo half-life to 24 hours. Once-daily administration thereby sustains stable blood drug concentrations throughout the day, laying a structural foundation for prolonged pharmacological effects.
Mechanism of Bidirectional Glucose Regulation
By targeted activation of GLP-1 receptors across multiple systemic tissues, liraglutide exerts intelligent bidirectional glycemic control aznd avoids the hypoglycemia risk prevalent in traditional hypoglycemic agents, featuring glucose-dependent glucose-lowering activity as its core advantage.
Under hyperglycemic conditions, the drug specifically activates GLP-1 receptors on pancreatic β-cells. Triggering the cyclic adenosine monophosphate (cAMP) signaling pathway facilitates intracellular calcium influx, accelerates synthesis and exocytosis of insulin granules, precisely elevates peripheral insulin levels, boosts glucose uptake and utilization, and efficiently reduces both postprandial and fasting blood glucose. Simultaneously, the drug acts on pancreatic α-cells to markedly suppress glucagon secretion. As a hyperglycemic hormone, reduced glucagon release inhibits hepatic glycogenolysis and gluconeogenesis, curbing endogenous glucose production and blocking pathways driving blood glucose elevation at the root.
When blood glucose remains normal or hypoglycemic, liraglutide's hypoglycemic potency spontaneously diminishes without overstimulating insulin secretion. The underlying principle lies in strict glucose dependence of GLP-1 receptor activation efficiency: under hypoglycemia, downstream signaling triggered by drug-receptor binding is drastically attenuated, precluding abnormal insulin surges and fully eliminating hypoglycemic risk. This intelligent bidirectional regulatory mechanism aligns liraglutide's glucose-lowering profile closely with physiological human glycemic homeostasis, delivering superior safety versus sulfonylureas, insulin and other conventional anti-diabetic medications. It is especially suitable for long-term administration in type 2 diabetes patients with severe glycemic fluctuations.
Mechanism of Body Weight and Appetite Regulation
Weight-lowering efficacy represents the core distinguishing feature of liraglutide capsule from classic hypoglycemic drugs, achieved via synergistic dual-target modulation of the central nervous system and gastrointestinal tract to deliver sustained, steady weight loss.At the central level, the drug crosses the blood-brain barrier to precisely activate GLP-1 receptors in the hypothalamic feeding center. It suppresses hunger signal transmission in the lateral hypothalamic area while stimulating satiety signals in the ventromedial region, centrally reducing appetite, curbing food cravings and attenuating neural impulses driving binge eating.
Additionally, liraglutide modulates central secretion of appetite-regulating hormones including dopamine and leptin, elevating the body's satiety threshold and prolonging satiety duration to cut total caloric intake fundamentally.
At the peripheral gastrointestinal level, liraglutide significantly delays gastric emptying and extends gastric food residence time, preventing sharp postprandial glycemic spikes while maintaining persistent satiety to reduce snacking and overeating.
Furthermore, the drug modulates intestinal flora composition and gut hormone secretion, inhibits adipocyte proliferation and lipid accumulation, promotes browning and catabolism of white adipose tissue, and accelerates breakdown of excess bodily fat.Unlike calorie-restriction dieting prone to weight rebound, liraglutide sustains long-term energy metabolic balance to lower body fat percentage and visceral fat deposition. Beyond weight reduction, it ameliorates metabolic disorders such as central obesity and insulin resistance, matching the comprehensive treatment demands of diabetic patients complicated with obesity.
Mechanism of Cardiovascular and Multi-Organ Protection
Liraglutide confers cardioprotective effects independent of its hypoglycemic and weight-loss functions, ranking among the limited hypoglycemic agents clinically proven to mitigate the risk of adverse cardiovascular events. Its protective mechanisms span blood vessels, myocardium and lipid metabolism.Vascular effects: The drug activates GLP-1 receptors on vascular endothelial cells to stimulate nitric oxide synthesis and release, ameliorating endothelial function.
It inhibits vascular smooth muscle cell proliferation and migration to retard atherosclerotic plaque formation and progression, while lowering vascular inflammatory factor levels to alleviate chronic inflammatory vascular injury.Lipid regulation: Liraglutide reduces total cholesterol, triglycerides and low-density lipoprotein cholesterol, elevates high-density lipoprotein cholesterol, alleviates dyslipidemia, decreases lipid deposition on vessel walls and lowers thrombotic risk.
Myocardial protection: It optimizes myocardial energy metabolism, alleviates myocardial ischemia-reperfusion injury, suppresses cardiomyocyte apoptosis, delays myocardial hypertrophy and ventricular remodeling, and enhances myocardial systolic function.
Abundant clinical trials confirm long-term liraglutide administration significantly cuts the incidence of major adverse cardiovascular events including myocardial infarction, stroke and cardiovascular death in type 2 diabetes patients. The drug also exerts moderate renal protective effects: it alleviates glomerular hyperfiltration, reduces urinary microalbumin excretion and slows the onset and progression of diabetic nephropathy. Through multi-organ targeted modulation, it enables integrated management of metabolic disorders and substantially improves patients' long-term prognosis.
Mechanism of Insulin Resistance Improvement
Insulin resistance constitutes the core pathological basis of type 2 diabetes, obesity and metabolic syndrome. Liraglutide gradually ameliorates systemic insulin resistance and restores impaired glucose metabolism via multiple signaling pathways.On one hand, weight loss and reduced visceral fat deposition decrease insulin-antagonizing substances such as free fatty acids and inflammatory factors released by adipose tissue, relieving lipid metabolic disorder-mediated inhibition of insulin signaling pathways and enhancing peripheral tissue insulin sensitivity.
On the other hand, liraglutide activates GLP-1 receptors in peripheral target organs including skeletal muscle and the liver. It facilitates skeletal muscle glucose uptake and oxidative utilization, restrains excessive hepatic gluconeogenesis, reduces ineffective insulin secretion and alleviates metabolic burden on pancreatic islet cells.
Moreover, the drug mitigates chronic low-grade systemic inflammation by downregulating expression of inflammatory factors such as tumor necrosis factor and interleukins, eliminating inflammation-induced blockade of insulin signaling and restoring insulin signal transduction. Long-term administration gradually reverses hyperinsulinemia, allowing pancreatic islet cells to rest and repair, slowing type 2 diabetes progression and enabling staged disease control. Standardized medication sustains stable long-term regulation of blood glucose and metabolic indicators in certain early-stage patients.
Pharmacokinetic Profiles
Liraglutide capsule is formulated with proprietary permeation-enhancing excipients to overcome the vulnerability of oral peptides to degradation by gastric acid and intestinal proteases, enabling gradual and gentle absorption after oral administration. Following single-dose administration, the time to maximum plasma concentration (Tmax) ranges from 8 to 12 hours. Plasma drug concentrations rise slowly with moderate peak levels without sharp concentration fluctuations. Once absorbed into systemic circulation, the palmitic acid side chain on the drug molecule undergoes reversible binding with plasma albumin, resulting in a plasma protein binding rate exceeding 98%. This binding drastically reduces renal glomerular filtration clearance, yielding a terminal elimination half-life of approximately 24 hours and supporting a convenient once-daily dosing regimen.
Steady-state plasma drug concentrations are achieved after 7 consecutive days of regular dosing, with minimal drug accumulation and no obvious risk of toxic buildup. This product is not metabolized via the cytochrome P450 enzyme system, thus eliminating drug-drug interactions with most agents cleared through CYP450 pathways. In vivo, the peptide backbone is predominantly hydrolyzed by non-specific endopeptidases and exopeptidases distributed throughout systemic tissues, generating short peptide fragments and amino acids devoid of pharmacological activity.
Metabolites are excreted via dual routes: urine and feces, with only trace amounts of intact parent drug eliminated through the kidneys. No dose adjustment is required for patients with mild to moderate hepatic or renal impairment.Food intake only slightly delays drug absorption rate without altering total systemic exposure reflected by the area under the concentration-time curve (AUC). Administration before or during meals exerts no material impact on overall therapeutic efficacy. Within the therapeutic dose range, administered dose exhibits linear correlation with in vivo drug exposure. Interindividual variability in pharmacokinetic parameters is low, plasma concentrations are highly controllable, and sustained stable blood drug levels are maintained with long-term dosing, facilitating continuous and steady regulation of metabolic indicators.
Industrial Synthetic Process of Liraglutide
The industrial-scale synthesis of liraglutide predominantly adopts Fmoc solid-phase peptide synthesis (SPPS) combined with refined post-synthetic modification procedures, enabling mass production of high-purity, high-activity drug molecules with a mature, purity-controllable overall process.
Fmoc-protected glycine resin serves as the solid-phase carrier. Following the C-terminal-to-N-terminal synthetic sequence, amino acid protecting groups are sequentially removed, and corresponding protected amino acids are coupled one by one via condensation reactions to assemble the complete liraglutide peptide backbone.
Upon full peptide chain assembly, trifluoroacetic acid cleavage reagent dissociates the crude peptide from the resin carrier and removes all side-chain protecting groups to yield unmodified liraglutide precursor peptide.
The critical modification step follows: mediated by a γ-glutamic acid linker, C16 palmitic fatty acid is site-specifically conjugated to the lysine residue at position 26 of the peptide chain to complete long-acting structural derivatization.
Subsequent procedures including centrifugation, liquid-liquid extraction, reverse-phase high-performance liquid chromatography (RP-HPLC) purification and lyophilization crystallization eliminate synthetic impurities and residual reagents, yielding high-purity liraglutide active pharmaceutical ingredient (API).
The API is then compounded with oral absorption-promoting excipients to manufacture the capsule formulations. The integrated synthetic process stably produces finished products complying with pharmaceutical standards, guaranteeing consistent drug bioactivity and safety.
FAQ
Is liraglutide a GLP-3?
+
-
Liraglutide is a derivative of GLP‐1 and shares 97% amino acid sequence homology with its parent molecule 9.
Hot Tags: liraglutide capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale